Skip to main content

Special Announcement


As a private teaching hospital wholly owned by The Chinese University of Hong Kong (CUHK), we prioritize the advancement of medical innovation and technology, as well as translational research, to improve patient care. We adhere to international guidelines and regulations, including Good Clinical Practice (GCP) and the Declaration of Helsinki, as well as other applicable international, national, or local ethical standards and regulatory requirements, to ensure the ethical conduct of our research endeavours.

To safeguard the rights and well-being of research participants, we have established the Clinical Research Ethics Committee (CREC) which served as an independent Institutional Review Board (IRB), the committee composed of multidisciplinary experts to review all research protocols involving human subjects, guaranteeing the protection and respect of their rights, safety and well-being. 

According to the U.S. regulations, any medical institution that wishes to be involved in any clinical study funded by the U.S. federal government or any U.S. governmental agencies (e.g. the U.S. National Institutes of Health (NIH) must use institutional review boards/research ethics committees (IRBs/RECs) registered with the U.S. Office for Human Research Protections (OHRP) for review and oversight of its clinical studies. To facilitate collaboration in international clinical research, CUHKMC CREC has registered with the OHRP.

IRB Name: CUHK Medical Centre Limited IRB #1

OHRP IRB No.: IRB00014308

Below are the researches being undertaken within CUHKMC in 2024:

Research safety is our top priority at CUHKMC. In 2023, we had no reported serious adverse events, negative feedback, or complaints related to our research activities.

If you are interested in learning more about the research policy at CUHKMC, please feel free to contact us at